Compare Sanofi SA (SNY) vs Cactus Inc. Class A Common Stock (WHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Cactus Inc. Class A Common Stock — how do they compare? Sanofi SA trades at $40.66 (market cap $96.38B), while Cactus Inc. Class A Common Stock trades at $62.37 (market cap $5.02B). The key difference: Sanofi SA is far larger — about 19.2× Cactus Inc. Class A Common Stock's market cap, and Sanofi SA pays the higher dividend (6.08%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Cactus Inc. Class A Common Stock for 0 Days on average.
| SNY | WHD | |
|---|---|---|
Market Cap | $96.38B | $5.02B |
Volume | 5,335,342 | 804,573 |
Sector | Health | Energy |
52-Week High | $52.34 | $73.73 |
52-Week Low | $39.12 | $35.26 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $115.67B | $4.71B |
Dividend Yield | 6.08% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $39.12, down 1.56% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, potentially driving future growth. Analyst consensus is mixed, with 44% buy ratings but a majority hold stance.
The outlook is cautiously optimistic, supported by earnings beats and strategic partnerships, but risks include a projected net income decline in 2026 and competitive pressures. The stock's current valuation metrics, such as a P/E of 22.06, appear reasonable relative to historical performance, though investor sentiment remains tempered by near-term challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Cactus Inc. Class A Common Stock
Cactus Inc. designs, manufactures, and rents wellhead and pressure control equipment for oil and gas drilling, completion, and production, operating under the Cactus Wellhead brand.
Read more on WHD →
